
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| immune system diseases | D007154 |
Brand Name | Status | Last Update |
|---|---|---|
| aubagio | New Drug Application | 2024-06-24 |
| teriflunomide | ANDA | 2025-04-11 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| relapsing-remitting multiple sclerosis | EFO_0003929 | D020529 | — |
Expiration | Code | ||
|---|---|---|---|
TERIFLUNOMIDE, AUBAGIO, SANOFI AVENTIS US | |||
| 2024-10-30 | PED | ||
| 2024-04-30 | M-61 | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, ACCORD HLTHCARE | |||
| 2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, AMNEAL PHARMS CO | |||
| 2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, APOTEX | |||
| 2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, AUROBINDO PHARMA | |||
| 2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, GLENMARK PHARMS | |||
| 2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, SANDOZ | |||
| 2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, TEVA PHARMS USA | |||
| 2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, WATSON LABS TEVA | |||
| 2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, ZYDUS PHARMS | |||
| 2023-09-08 | PC | ||

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 9 | 26 | 5 | 29 | 70 |
| Sclerosis | D012598 | — | — | — | 4 | 20 | 4 | 17 | 45 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | 14 | 2 | 9 | 25 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | 2 | 1 | — | — | 3 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | — | 1 | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 4 | — | — | — | 4 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 3 | — | — | — | 3 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 1 | — | — | — | 1 |
| Breast diseases | D001941 | — | N60-N65 | 1 | 1 | — | — | — | 1 |
| Celiac disease | D002446 | EFO_0001060 | K90.0 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 1 | 3 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | — | — | — | 1 | 1 |
| Herpesviridae infections | D006566 | EFO_0007309 | B00.4 | — | — | — | — | 1 | 1 |
| Viremia | D014766 | — | B34.9 | — | — | — | — | 1 | 1 |
| Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | — | — | — | — | 1 | 1 |
| Demyelinating diseases | D003711 | — | — | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | — | — | 1 | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | — | — | — | 1 | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Teriflunomide |
| INN | teriflunomide |
| Description | Teriflunomide is an enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the anilino group of 4-(trifluoromethyl)aniline. Used for the treatment of relapsing forms of multiple sclerosis and rheumatoid arthritis. It has a role as an EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor, a tyrosine kinase inhibitor, a hepatotoxic agent, a drug metabolite and a non-steroidal anti-inflammatory drug. It is a nitrile, an enol, an aromatic amide, an enamide, a member of (trifluoromethyl)benzenes and a secondary carboxamide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1 |
| PDB | — |
| CAS-ID | 163451-81-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL973 |
| ChEBI ID | 68540 |
| PubChem CID | 54684141 |
| DrugBank | DB08880 |
| UNII ID | 1C058IKG3B (ChemIDplus, GSRS) |



